Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4437-4440

  Betancort, Juan M ^a   Winn, David T ^a   Liu, Ruzhang ^b   Xu, Quansheng ^b   Liu, Junjuan ^b   Liao, Wensheng ^b   Chen, Shu Hui ^b   Carney, David ^a   Hanway, Denise ^a   Schmeits, James ^a   Li, Xinqiang ^a   Gordon, Eric ^a   Campbell, David A ^a  

^a Phenomix Corporation   (United States)

^b WUXI APPTEC   (China)

Author keywords

Cyanopyrrolidine; Diabetes; DPP4

Indexed keywords

BICYCLIC CYANOTHIAZOLIDINE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMISTRY; DRUG STRUCTURE; DRUG SYNTHESIS;

AZABICYCLO COMPOUNDS; CATALYSIS; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NITRILES; PROTEIN STRUCTURE, TERTIARY; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINES; TIME FACTORS;

EID: 67649950033     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.048     Document Type: Article

References (31)

1. Ross S.A., Gulve E.A., and Wang M. Chem. Rev. 104 (2004) 1255
2. Patel M., and Rybczynski P. Exp. Opin. Invest. Drugs 12 (2003) 623
3. Arulmozhi D.K., and Portha B. Eur. J. Pharm. Sci. 28 (2006) 96
4. Knudsen L.B. J. Med. Chem. 47 (2004) 4128
5. Orsakov C. Diabetologia 35 (1992) 701
6. Augustyns K., Van der Veken P., Senten K., and Haemers A. Curr. Med. Chem. 12 (2005) 971
7. Weber A.E. J. Med. Chem. 47 (2004) 4135
8. Drucker D.J. Exp. Opin. Invest. Drugs 12 (2003) 87
9. Pospisilik A., Martin J., Doty T., Ehses J.A., Pamir N., Lynn F.C., Piteau S., Demuth H.-U., McIntosh C.H.S., and Pederson R.A. Diabetes 52 (2003) 741
10. Herman G.A., Bergman A., Stevens C., Kotey P., Yi B.M., Zhao P., Dietrich B., Golor G., Schroedter A., Keymeulen B., Lasseter K.C., Kipnes M.S., Snyder K., Hilliard D., Tanen M., Cilissen C., De Smet M., Lepeleire I., Van Dyck K., Wang A.Q., Zeng W., Davies M.J., Tanaka W., Holst J.J., Deacon C.F., Gottesdiener K.M., and Wagner J.A. J. Clin. Endocrinol. Metab. 91 (2006) 4612
11. Ahren B., Pacini G., Foley J.E., and Schweizer A. Diabetes Care 28 (2005) 1936
12. Thornberry N.A., and Weber A.E. Curr. Top. Med. Chem. 7 (2007) 557
13. Peters J.-U. Curr. Top. Med. Chem. 7 (2007) 579
14. Madar D.J., Kopecka H., Pireh D., Yong H., Pei Z., Li X., Wiedeman P.E., Djuric S.W., Von Geldern T.W., Fickes M.G., Bhagavatula L., McDermott T., Wittenberger S., Richards S.J., Longenecker K.L., Stewart K.D., Lubben T.H., Ballaron S.J., Stashko M.A., Long M.A., Wells H., Zinker B.A., Mika Am.K., Beno D.W.A., Kempf-Grote A.J., Polakowski J., Segreti J., Reinhart G.A., Fryer R.M., Sham H.L., and Trevillyan J.M. J. Med. Chem. 49 (2006) 6416
15. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., Han S.-P., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G.E., Egan D.M., Marcinkeviciene J., Chang S.Y., Biller S.A., Kirby M.S., Parker R.A., and Hamann L.G. J. Med. Chem. 48 (2005) 5025
16. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E. J. Med. Chem. 46 (2003) 2774
17. See for example Ref. 6d and. Sakashita H., Akahoshi F., Kitajima H., Tsutsumiuchi R., and Hayashi Y. Bioorg. Med. Chem. 14 (2006) 3662
18. Oefner C., D'Arcy A., Sweeney A.M., Pierau S., Gardiner R., and Dale G.E. Acta Crystallogr., Sect. D 59 (2003) 1206
19. Rasmussen H.B., Branner S., Wiberg F.C., and Wagtmann N. Nat. Struct. Biol. 10 (2003) 19
20. Campbell, D. A.; Betancort, J. M.; Winn, D. T. U.S. Patent Application 06/009518A1.
21. Heins J., Welker P., Schonlein C., Born I., Hartrodt B., Neubert K., Tsuru D., and Barth A. Biochim. Biophys. Acta 954 (1988) 161
22. Baldwin J.E., Freeman R.T., Lowe C., Schofield C.J., and Lee E. Tetrahedron 45 (1989) 4537
23. Compound 6 was prepared from Fmoc-BTD purchased from Neosystems (Cat. No. FB02601).
24. The amine and cyano groups adopt a relative spatial arrangement similar to the one observed in the X-ray co-crystal structure of BMS-477118 (Saxagliptin, 3) complexed with DPP4. Metzler W.J., Yanchunas J., Weigelt C., Kish K., Klei H.E., Xie D., Zhang Y., Corbett M., Tamura J.K., He B., Hamann L.G., Kirby M.S., and Marcinkeviciene J. Protein Sci. 17 (2008) 412
25. Szardenings A.K., Burkoth T.S., Look G.C., and Campbell D.A. J. Org. Chem. 61 (1996) 6720
26. Fuchi N., Doi T., Harada T., Urban J., Cao B., Kahn M., and Takahashi T. Tetrahedron Lett. 42 (2001) 1305
27. Extensive NOE studies were carried out in conjunction with X-ray structure determination of a key intermediate in order to assign the stereochemistry. See:. Liu R., Wu Y., Li Q., Liao W., Chen S.-H., Li G., Betancort J.M., Winn D.T., and Campbell D.A. Tetrahedron 64 (2008) 4363
28. 90 calculations were performed by nonlinear regression analysis using Prism software (GraphPad Software, Inc., San Diego, CA).
29. Sedo A., and Malik R. Biochim. Biophys. Acta 1550 (2001) 107
30. Rummey C., and Metz G. Proteins 66 (2007) 160
31. In the course of the preparation of this manuscript we became aware of simultaneous efforts by other researchers around some of the compounds described in this manuscript. See: Wagner, H.; Schoenafinger, K.; Jaehne, G.; Gaul, H.; Buning, C.; Tschank, G.; Werner, U. PCT Patent Application WO 05/012312A1.